Cargando…
Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers
Metastatic cancers harbor complex genomic alterations. Thus, monotherapies are often suboptimal. Individualized combinations are needed in order to attenuate resistance. To help inform selection of safe starting doses for novel, two-agent, targeted drug combinations, we identified clinical trials in...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905475/ https://www.ncbi.nlm.nih.gov/pubmed/26824502 http://dx.doi.org/10.18632/oncotarget.7023 |